Large fluctuations indicate high exposure to foreign currency risk within restructuring-related liabilities.
Captures adjustments to restructuring reserves resulting from foreign currency exchange rate fluctuations and other misc...
Standard for multinational corporations with global restructuring footprints.
other_restructuring_reserve_translation_and_other_adjustment| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| North American Pharmaceutical | — | — | — | — | — | — | — | -$1.00M |
| Medical-Surgical Solutions | $0.00 | $0.00 | -$2.00M | $0.00 | $500.00K | $500.00K | $500.00K | $500.00K |
| International | -$1.00M | -$4.00M | -$1.00M | -$1.00M | — | — | — | — |
| Prescription Technology Solutions | -$2.00M | — | — | — | — | — | — | $0.00 |
| U.S. Pharmaceutical | -$1.00M | — | — | — | — | — | — | — |
| Total | — | — | — | — | — | — | — | — |
Oncology & Multispecialty is derived from annual filings.
International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.